Risedronate Sodium Tablet, Film Coated
Product Images NDC 33342-108

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 33342-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Risedronate 30 mg 30s Carton

Packaging label for Risedronate Sodium Tablets, USP 30 mg, film-coated oral tablets. The label includes the Macleods Pharma USA logo, mentions the product is Rx only, and contains 30 tablets in unit-dose packaging. It is manufactured by Macleods Pharmaceuticals Ltd, India, and labeled for Macleods Pharma USA, Inc. Storage and dosage information references are included.*

FDA Label Image

Risedronate 30 mg 500s Container

Label for Risedronate Sodium Tablets, USP 30 mg, film-coated tablets by Macleods Pharmaceuticals Limited. The label notes 'Once-a-day' dosing, includes storage instructions (20° to 25°C, excursions permitted 15°C to 30°C), and cautions to keep out of reach of children. It states the product is manufactured for Macleods Pharma USA, Inc. and contains 500 tablets. Pharmacists are advised to dispense the accompanying Medication Guide.*

FDA Label Image

30-30-container (Risedronate 30mg 30s Container)

Label for Risedronate Sodium Tablets, USP 30 mg film-coated oral tablets by Macleods Pharmaceuticals Limited. It states 'Once-a-day' dosing and contains 30 tablets per bottle. The label specifies storage instructions, dosage referencing prescribing information, and the manufacturer location as Macleods Pharma USA, Inc., Princeton, NJ and Macleods Pharmaceuticals Ltd., India.*

FDA Label Image

Risedronate 5 mg 2000s Container

Label for Risedronate Sodium 5 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label states each tablet contains 5 mg Risedronate Sodium, USP, with storage instructions at 20° to 25°C and a note to dispense the accompanying Medication Guide. The package contains 2000 tablets and includes manufacturer and distributor information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.*

FDA Label Image

Risedronate 5 mg 30s Carton

Packaging label for Risedronate Sodium Tablets, USP 5 mg, film-coated oral tablets by Macleods Pharmaceuticals Limited. The label indicates a package of 30 tablets (3 x 10 unit-dose tablets), featuring storage instructions, manufacturer details, a barcode, and the labeler as Macleods Pharma USA, Inc.*

FDA Label Image

Risedronate 5 mg 30s Container

Packaging label for Risedronate Sodium Tablets, USP 5 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label indicates a 30-tablet count, mentions 'Once-a-day' dosing, and includes storage instructions and manufacturer details for Macleods Pharma USA, Inc., and Macleods Pharmaceuticals Ltd.*

FDA Label Image

Risedronate Carton 35 mg 12 Tablets

Packaging label for Risedronate Sodium Tablets USP 35 mg, film-coated oral tablets by Macleods Pharmaceuticals Limited. The label states the product is a once-a-week prescription medication with 12 tablets per package (3 packs of 4 tablets each). It includes manufacturer information, barcode, storage instructions, and instructions for taking the tablet, emphasizing swallowing a whole tablet in the morning with water and not lying down or eating for 30 minutes afterward.*

FDA Label Image

Risedronate Carton 35 mg 4 Tablets

Packaging label for Risedronate Sodium Tablets, USP 35 mg, film-coated oral tablets manufactured by Macleods Pharmaceuticals Limited. The label shows a 4-week supply containing 4 tablets. It includes instructions for use, storage information, and manufacturer details. The label also highlights the 35 mg strength and the once-a-week dosing schedule.*

FDA Label Image

123 (Risedronate Fig 1)

A bar chart titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA.' It compares the percentage of patients experiencing fractures at various sites—including all sites, wrist, humerus, hip, pelvis, leg, and clavicle—between placebo and risedronate sodium tablets 5 mg groups. The chart shows lower fracture rates for the risedronate group compared to placebo across most fracture sites.*

FDA Label Image

456 (Risedronate Fig 2)

A bar graph titled 'Figure 2 Change in BMD from Baseline 2-Year Prevention Study' comparing mean percentage changes in bone mineral density (BMD) at three sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. It displays data for placebo and Risedronate sodium 5 mg tablets, showing increases in BMD with Risedronate sodium relative to placebo at all sites.*

FDA Label Image

159 (Risedronate Fig 3)

A bar chart showing the mean percentage change in bone mineral density (BMD) from baseline at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart compares placebo (white bars) and Risedronate Sodium 5 mg (black bars) in patients recently initiating glucocorticoid therapy, including sample sizes for each group. Error bars represent standard error.*

FDA Label Image

156 (Risedronate Fig 4)

A bar chart titled 'Change in BMD from Baseline Patients on Long-Term Glucocorticoid Therapy' comparing placebo and Risedronate Sodium 5 mg effects on bone mineral density (BMD) measurements at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart depicts mean percentage changes with standard error bars for each group.*

FDA Label Image

125 (Risedronate Fig 5)

A bar graph showing the incidence percentage of vertebral fractures in patients either continuing or initiating glucocorticoid therapy. It compares placebo and Risedronate Sodium 5 mg groups with separate bars for patients continuing treatment, patients initiating treatment, and a combined group. Numeric sample sizes (n) are noted for each group.*

FDA Label Image

129 (Risedronate Fig 6)

A line graph depicting the mean percent change from baseline in serum alkaline phosphatase excess over visit days up to 600 days, comparing DIDRONE 400 mg and Risedronate Sodium 30 mg treatments. The graph shows percent change on the Y-axis and visit days on the X-axis during treatment, follow-up, and extended follow-up periods, with sample sizes indicated for each time point.*

FDA Label Image

Srtuct (Risedronate Structure)

Chemical structure of Risedronate Sodium, showing its molecular arrangement including phosphate groups, a pyridine ring, and associated hydration (2.5 molecules of water).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.